- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Early this morning in Vienna, Austria, the United Nations Commission on Narcotic Drugs (CND) made a historic decision to adopt the World Health Organization’s (WHO) recommendation to remove cannabis and its resin from Schedule IV under the United Nations (UN) Single Convention on Narcotic Drugs of 1961.
The CND, made up of 53 member countries is responsible for implementing international drug control treaties as well as the Scheduling of drugs. A total of 27 countries voted in favor of the removal of cannabis from Schedule IV, including the United States. This decision to remove cannabis from Schedule IV comes after 60 years since its placement into this strictest international category, which is intended for drugs that are dangerous and lack medical use.
Americans for Safe Access (ASA) and its program, the International Medical Cannabis Patients Coalition (IMCPC), which is the largest coalition of medical cannabis patient organizations in the world, have been fighting to remove cannabis from Schedule IV at the United Nations for over a decade because it was outdated, not based on scientific evidence, and has been harmful to the millions of patients around the world who use cannabis for therapeutic purposes. ASA along with members of IMCPC have testified before the UN and the World Health Organization (WHO), and lobbied member states for many years. Through ASA and IMCPC, patients have had international representation at the WHO and the United Nations and generated thousands of letters from over 75 countries to UN Ambassadors calling for reconsiderations of Cannabis’ scheduling. In 2016, ASA and the IMCPC created its own critical review that was delivered to the UN, which helped prompt the review process to look at the science and policies related to medical cannabis.
Before the CND could vote on this measure today, it was required to review and base its vote on the WHO’s recommendations. The WHO, in turn, was required to obtain recommendations on cannabis by an independent, scientific advisory body called the Expert Committee on Drug Dependence (ECDD) before it could offer its recommendations to the CND. After many years of pressure, the ECDD was able to conduct a rigorous, evidence-based, and multi-year review of cannabis and its resin that, ultimately, determined that cannabis and its resin be removed from Schedule IV.
The deletion of cannabis in Schedule IV has far and wide implications for medical cannabis patients around the world:
- Countries can now allow more research of cannabis to be conducted for medical use.
- Countries that have not yet provided access to medical cannabis will no longer be able to use this archaic Scheduling as an excuse to block medical cannabis reform.
- Countries can finally work to move past some of the harms inflicted on medical cannabis patients, including incarceration, fines, and negative stigma.
The MORE Act, which is being considered before the full US House of Representatives tomorrow seeks to deschedule cannabis from Schedule I of the US Controlled Substances Act. Should the bill fail in the House and/or the Senate, ASA recommends that the US reschedule cannabis to a new Schedule V(A) that would allow for cannabis to be used as a frontline medication.
After that, ASA strongly urges the U.S. to adopt ASA’s draft federal legislation that would create an Office of Medical Cannabis Control (OMCC), a federal oversight agency with centralized regulatory authority over medical cannabis research, production, and distribution. While passage of the MORE Act would do much to help medical cannabis patients, more must be done for the millions of Americans struggling with debilitating illness and chronic pain. This new federal agency would result in a consistent and predictable regulatory environment nationwide.
The UN decision today gives us strength and hope. ASA will continue our fight for access until all patients in the US and across the globe have access to this incredible medicine.